Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
Published . Updated .
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.
Directly affected
Indirectly affected
- GIEQ GOLDMAN SACHS ETF TR DATA ENHA
GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- RACK VANECK ETF TR VANECK DATA CENT
GA selected RACK as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.
Source: BioPharma Dive
The price since 5 Oct 2026: Vaxcyte (PCVX) versus the S&P 500
Since the first closing price after “Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data,” Vaxcyte (PCVX) is -4.60%. The S&P 500 fund (SPY) is -1.60% over the same days, a -2.99% difference versus the market.
Who gains and who loses around Vaxcyte (PCVX)
Companies carried with this story
- PCVX Vaxcyte
In “Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data,” Vaxcyte (PCVX) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names VAXCYTE INC in the headline; GA resolved that company to PCVX
- GIEQ Goldman Sachs Etf Tr Data Enha
Goldman Sachs Etf Tr Data Enha (GIEQ) is linked, with no stored direction, medium confidence in the 5 Oct 2026 story “Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data.” Reason on file: GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- RACK Vaneck Etf Tr Vaneck Data Cent
In “Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data,” Vaneck Etf Tr Vaneck Data Cent (RACK) is linked, with no stored direction, medium confidence. Reason on file: GA selected RACK as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Vaxcyte (PCVX)
The 5 Oct 2026 story “Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data” names Vaxcyte (PCVX) because of this story.
The link for Vaxcyte (PCVX) is this: The reported development directly names VAXCYTE INC in the headline; GA resolved that company to PCVX
A second company, Goldman Sachs Etf Tr Data Enha (GIEQ), is listed for a different reason: GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Vaxcyte (PCVX)
GIEQ traded between 41.01 and 42.36 across 6 sessions. The latest close on file is 41.10. PCVX traded between 55.85 and 90.48 across 14 sessions. The latest close on file is 63.69. RACK traded between 44.78 and 51.45 across 20 sessions. The latest close on file is 44.78.
How strong the case is around Vaxcyte (PCVX)
27 out of 100
“Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data” scores 27 out of 100. The score uses 1 sources, and 3 linked companies.